FDA Grants Approval for Dalbavancin Hydrochloride ANDA219604
The FDA has granted approval for the ANDA219604 application for Dalbavancin Hydrochloride submitted by BE PHARMS.
Published: July 25, 2026
Updated: July 25, 2026
Author: Humanexa Intelligence
Therapeutic area: Infectious Disease / Antibiotic
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
high
Signalhigh
Confidencehigh
Why it matters
The FDA's approval of BE PHARMS' generic Dalbavancin Hydrochloride is significant as it introduces increased competition in the antibiotic market. Portfolio teams must evaluate the implications for existing products to safeguard market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and pricing strategies of BE PHARMS following this approval.
Related companies & assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.